尼日利亚 - 英文 - NAFDAC (National Agency for Food and Drugs Administration and Control)

dafra pharma gmbh - artesunate, sulfamethoxypyrazine, pyrimethamine - tablets - co-arinate is used as curative treatment for all forms of malaria, including severe malaria caused by multi drug-resistant strains of plasmodium falciparum. in case of p. vivax addition of primaquine may be required. co-arinate has been especially designed to treat malaria in children, adolescents and adults.

尼日利亚 - 英文 - NAFDAC (National Agency for Food and Drugs Administration and Control)

dafra pharma gmbh - artesunate, sulfamethoxypyrazine, pyrimethamine - tablets - co-arinate is used as curative treatment for all forms of malaria, including severe malaria caused by multi drug-resistant strains of plasmodium falciparum. in case of p. vivax addition of primaquine may be required. co-arinate has been especially designed to treat malaria in children, adolescents and adults.

爱尔兰 - 英文 - HPRA (Health Products Regulatory Authority)

pharma regulatory solutions ltd - voriconazole - pdr for soln for infusion - 200 milligram - triazole derivatives - antimycotics for systemic use, triazole derivatives - voriconazole is a broad-spectrum, triazole antifungal agent and is indicated in adults and children aged 2 years and above as follows: treatment of invasive aspergillosis. treatment of candidaemia in non-neutropenic patients. treatment of fluconazole-resistant serious invasive candida infections (including c. krusei). treatment of serious fungal infections caused by scedosporium spp. and fusarium spp. voriconazole should be administered primarily to patients with progressive, possibly life-threatening infections. prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (hsct) recipients.

菲律宾 - 英文 - FDA (Food And Drug Administration)

sun pharma philippines, inc.; distributor: adp pharma corporation - co-amoxiclav - film-coated tablet - 625mg

菲律宾 - 英文 - FDA (Food And Drug Administration)

metz pharma'l inc - co-amoxiclav - powder for oral suspension - 400mg + 57mg per 5ml

菲律宾 - 英文 - FDA (Food And Drug Administration)

metz pharma'l inc - co-amoxiclav - powder for oral suspension - 200mg + 28.5mg per 5ml

菲律宾 - 英文 - FDA (Food And Drug Administration)

the generics pharmacy, inc - co-amoxiclav - powder for suspension - 400 mg/57 ml

欧盟 - 英文 - EMA (European Medicines Agency)

teva pharma b.v. - budesonide, formoterol - asthma - drugs for obstructive airway diseases, - budesonide/formoterol teva pharma b.v. is indicated in adults 18 years of age and older only.asthmabudesonide/formoterol teva pharma b.v. is indicated in the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β2 adrenoceptor agonist) is appropriate: orin patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β2 adrenoceptor agonists.in patients already adequately controlled on both inhaled corticosteroids and long-acting β2 adrenoceptor agonists. 

欧盟 - 英文 - EMA (European Medicines Agency)

acino pharma gmbh  - clopidogrel - peripheral vascular diseases - antithrombotic agents - clopidogrel is indicated in adults for the prevention of atherothrombotic events in:patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.patients suffering from acute coronary syndrome:- non st segment elevation acute coronary syndrome (unstable angina or non q wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa).- st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy.for further information please refer to section 5.1.

欧盟 - 英文 - EMA (European Medicines Agency)

teva pharma b.v.  - clopidogrel (as hydrobromide) - peripheral vascular diseases; acute coronary syndrome; myocardial infarction; stroke - antithrombotic agents - prevention of atherothrombotic eventsclopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease;adult patients suffering from acute coronary syndrome: non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa);st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy.prevention of atherothrombotic and thromboembolic events in atrial fibrillationin adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin-k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke.